Mayne Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference ADELAIDE, Australia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the 42nd Annual J.P. Morgan Healthcare Conference as follows: Date: Thursday, January 11, 2024Time: 7:30am PST / 10:30 am ESTWebcast: The live and archived webcast of the presentation will be accessible from the Company’s website under Investor Relations. The replay of the webcast will be accessible for 30 days. To sche...
A director at Mayne Pharma Group Limited maiden bought 37,041 shares at 3.804AUD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
The independent financial analyst theScreener just awarded an improved star rating to MAYNE PHARMA (AU), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date February 11, 2022, the closing...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Despite many Australian-listed healthcare stocks we cover having substantial revenue exposure to the U.S., the latest potential regulatory changes in that market pose a low risk to our fair value estimates. The cost of and access to healthcare is an emotive topic among U.S. voters and hence at the forefront of political agendas. Of relevance to the Australian companies that operate in the U.S. is the draft Lower Health Care Costs Act, or LHCCA, which aims to improve transparency in the healthcar...
Despite many Australian-listed healthcare stocks we cover having substantial revenue exposure to the U.S., the latest potential regulatory changes in that market pose a low risk to our fair value estimates. The cost of and access to healthcare is an emotive topic among U.S. voters and hence at the forefront of political agendas. Of relevance to the Australian companies who operate in the U.S. is the draft Lower Health Care Costs Act, or LHCCA, which aims to improve transparency in the healthcare...
The negative 10-month trading update provided by no-moat Mayne Pharma follows a challenging half-year result reported in February, and was largely factored into our base case for fiscal 2019. However, continued competitive forces in generic pharmaceuticals in the U.S. results in a reduction in our fair value estimate to AUD 1.00 from AUD 1.05. Revenue in the key generic products segment is down 15% year to date primarily as result of increased competition and the negative effect on pricing. We n...
Through a series of acquisitions, Mayne Pharma has transformed into a vertically integrated specialty drug manufacturer with proprietary drug delivery expertise and a substantial product portfolio. The company’s stated strategy is heavily geared towards the timely introduction of enhanced generic formulations targeting niche markets, primarily in the U.S., which has been significantly expanded with the Teva generic portfolio acquisition. In the medium term, the company aims to win significant ...
The negative 10-month trading update provided by no-moat Mayne Pharma follows a challenging half-year result reported in February, and was largely factored into our base case for fiscal 2019. However, continued competitive forces in generic pharmaceuticals in the U.S. results in a reduction in our fair value estimate to AUD 1.00 from AUD 1.05. Revenue in the key generic products segment is down 15% year to date primarily as result of increased competition and the negative effect on pricing. We n...
No-moat-rated Mayne reported a first-half result below our expectations, despite improvement on the previous corresponding period, or pcp, across key metrics. This included a 13% increase in revenue on the pcp to AUD 274.4 million, a 16% increase in underlying EBITDA to AUD 81.2 million, and a 35% increase in underlying net profit after tax to AUD 21.1 million, with all slightly under our full-year expectations. Except for the highly competitive generic products division, or GPD, all segments ex...
No-moat-rated Mayne reported a first-half result below our expectations, despite improvement on the previous corresponding period, or pcp, across key metrics. This included a 13% increase in revenue on the pcp to AUD 274.4 million, a 16% increase in underlying EBITDA to AUD 81.2 million, and a 35% increase in underlying net profit after tax to AUD 21.1 million, with all slightly under our full-year expectations. Except for the highly competitive generic products division, or GPD, all segments e...
Through a series of acquisitions, Mayne Pharma has transformed into a vertically integrated specialty drug manufacturer with proprietary drug delivery expertise and a substantial product portfolio. The company’s stated strategy is heavily geared towards the timely introduction of enhanced generic formulations targeting niche markets, primarily in the U.S., which has been significantly expanded with the Teva generic portfolio acquisition. In the medium term, the company aims to win significant ...
No-moat Mayne Pharma’s reported sales for the first four months of fiscal 2019 put the firm on track to meet our full-year forecast. Revenue increased 21% to AUD 183 million versus the previous corresponding period, or pcp, driven by steady performance in the core generic drug division, rising contribution from specialty products, and solid gains in contract services and international sales. While the performance suggests a full-year run rate of about AUD 550 million, 4% below our AUD 570 mill...
No-moat Mayne Pharma’s reported sales for the first four months of fiscal 2019 put the firm on track to meet our full-year forecast. Revenue increased 21% to AUD 183 million versus the previous corresponding period, or pcp, driven by steady performance in the core generic drug division, rising contribution from specialty products, and solid gains in contract services and international sales. While the performance suggests a full-year run rate of about AUD 550 million, 4% below our AUD 570 mill...
No-moat Mayne Pharma’s reported sales for the first four months of fiscal 2019 put the firm on track to meet our full-year forecast. Revenue increased 21% to AUD 183 million versus the previous corresponding period, or pcp, driven by steady performance in the core generic drug division, rising contribution from specialty products, and solid gains in contract services and international sales. While the performance suggests a full-year run rate of about AUD 550 million, 4% below our AUD 570 mill...
We maintain our AUD 1.30 per share fair value estimate for no-moat Mayne Pharma, and our very high uncertainty rating, after transferring coverage to a new analyst. Our long-term outlook is mostly unchanged. We continue to expect Mayne will continue to build scale by capturing profitable and sizable market shares in niche drug segments, through new product introductions or acquisitions that can sustain only a limited number of participants. To this end, we’re encouraged by the company’s num...
Through a series of acquisitions, Mayne Pharma has transformed into a vertically integrated specialty drug manufacturer with proprietary drug delivery expertise and a substantial product portfolio. The company’s stated strategy is heavily geared towards the timely introduction of enhanced generic formulations targeting niche markets, primarily in the U.S., which has been significantly expanded with the Teva generic portfolio acquisition. In the medium term, the company aims to win significant ...
We maintain our AUD 1.30 per share fair value estimate for no-moat Mayne Pharma, and our very high uncertainty rating, after transferring coverage to a new analyst. Our long-term outlook is mostly unchanged. We continue to expect Mayne will continue to build scale by capturing profitable and sizable market shares in niche drug segments, through new product introductions or acquisitions that can sustain only a limited number of participants. To this end, we’re encouraged by the company’s n...
We are not making any changes to our AUD 1.30 fair value estimate or no-moat rating for Mayne Pharma after the company reported full-year results slightly ahead our expectations, with adjusted EBITDA of AUD 165.3 million versus our forecast USD 158 million. Despite the ongoing momentum in the second half, and management’s positive comments regarding a more stabilised generic pricing environment, there was little in the briefing that would alter our medium-term view of the company. At current l...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.